A total of 43 partners have decided to join forces to support and push forward our initiatives. This represents a major change in philosophy that has already started generating significant output on all projects. Our corporate partners especially are getting out of the competitive mode in order to have a positive societal impact and operate in a positive societal environment. We believe the full benefits of co-creation and collaboration are yet to be seen.
new partners, bringing us to a total of 43
of funding raised
experts in our patient engagement ecosystem
experts in our dengue ecosystem
visits on our projects websites
followers of our social channels
people saw our messages on social media
people actively engaged on social media
'I truly believe what we’ve seen so far is many individual initiative that have really not talked to each other, that sometimes duplicated the work and here with PFMD our ultimate goal is to bring access to patients in a much more efficient way for new medicines. PFMD can bring all these stakeholders together. First of all can map all the initiatives, secondly reach a consensus what the best instruments, the best framework would be, the best tools would be to really create meaningful patient engagement. And third, it can then develop a framework that would be applicable for all stakeholders and would ultimately again lead to much much better medicines to patients."
Head of Medical, Amgen Europe
"PFMD is a transatlantic group with a global intent from the start. The mutual respect of stakeholder members and contributors is a fertile ground for co-creating tools we all need to ensure the next horizons of patient involvement in development of new therapies. I’m grateful for what the Synergist brings as experts in convening diverse stakeholders and a vision for meaningful change in the world."
Global Public Affairs Lead, Pfizer